FDA authorizes drug combination for treatment of COVID-19
The FDA issued an emergency use authorization for a drug combination to treat COVID-19.
The drugs are Eli Lilly's baricitinib and Gilead's remdesivir, the latter of which was given to President Donald Trump as part of his coronavirus treatment.
The authorization is only for hospitalized adults and children 2 years of age or older who need help breathing.
Baricitinib, which is used to treat rheumatoid arthritis, is not authorized as a stand-alone treatment for COVID-19. It must be used in combination with remdesivir.
A Phase 3 study found that when used with remdesivir, the combination helped hospitalized patients recover faster than remdesivir alone, cutting the median time to recovery by about one day.
ABC News' Sony Salzman contributed to this report